Spots Global Cancer Trial Database for recurrent pancreatic carcinoma

Every month we try and update this database with for recurrent pancreatic carcinoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Vismodegib and Gemcitabine Hydrochloride in Treating Patients With Advanced Pancreatic Cancer	NCT01195415	Recurrent Pancr... Stage IV Pancre...	Gemcitabine Hyd... Laboratory Biom... Vismodegib	18 Years -	National Cancer Institute (NCI)
TLR8 Agonist VTX-2337 and Cyclophosphamide in Treating Patients With Metastatic, Persistent, Recurrent, or Progressive Solid Tumors	NCT02650635	Colorectal Aden... Metastatic Panc... Recurrent Breas... Recurrent Color... Recurrent Melan... Recurrent Non-S... Recurrent Pancr... Recurrent Renal... Solid Neoplasm Stage IV Breast... Stage IV Non-Sm... Stage IV Renal ... Stage IV Skin M... Stage IVA Color... Stage IVA Pancr... Stage IVB Color... Stage IVB Pancr...	Cyclophosphamid... Laboratory Biom... Pegfilgrastim Pharmacological... TLR8 Agonist VT...	18 Years -	Mayo Clinic
Pembrolizumab and XL888 in Patients With Advanced Gastrointestinal Cancer	NCT03095781	Colorectal Aden... Metastatic Panc... Recurrent Color... Recurrent Pancr... Stage III Color... Stage III Pancr... Stage IIIA Colo... Stage IIIB Colo... Stage IV Colore... Stage IV Pancre... Stage IVA Color... Stage IVA Pancr... Stage IVB Color... Stage IVB Pancr... Unresectable Pa...	XL888 Pembrolizumab	18 Years -	Emory University
Carboplatin and Paclitaxel With or Without Viral Therapy in Treating Patients With Recurrent or Metastatic Pancreatic Cancer	NCT01280058	Pancreatic Acin... Pancreatic Duct... Recurrent Pancr... Stage IV Pancre...	Carboplatin Laboratory Biom... Paclitaxel Wild-type Reovi...	18 Years -	National Cancer Institute (NCI)
Selumetinib and Akt Inhibitor MK2206 or mFOLFOX Therapy Comprising Oxaliplatin and Fluorouracil in Treating Patients With Metastatic Pancreatic Cancer Previously Treated With Chemotherapy	NCT01658943	Pancreatic Acin... Pancreatic Duct... Recurrent Pancr... Stage IV Pancre...	Akt Inhibitor M... Fluorouracil Oxaliplatin Selumetinib	18 Years -	National Cancer Institute (NCI)
Carboplatin and Paclitaxel With or Without Viral Therapy in Treating Patients With Recurrent or Metastatic Pancreatic Cancer	NCT01280058	Pancreatic Acin... Pancreatic Duct... Recurrent Pancr... Stage IV Pancre...	Carboplatin Laboratory Biom... Paclitaxel Wild-type Reovi...	18 Years -	National Cancer Institute (NCI)
Neoadjuvant Chemotherapy Followed by Radiation Therapy and Gemcitabine/Sorafenib/Vorinostat in Pancreatic Cancer	NCT02349867	Pancreatic Aden... Stage IA Pancre... Stage IB Pancre... Stage IIA Pancr... Stage IIB Pancr... Stage III Pancr... Recurrent Pancr...	Gemcitabine Sorafenib Vorinostat 3-Dimensional C... Intensity-Modul... RosetteSep DEPfff	18 Years -	Virginia Commonwealth University
Ascorbic Acid and Combination Chemotherapy in Treating Patients With Locally Advanced or Recurrent Pancreatic Cancer That Cannot Be Removed by Surgery	NCT02896907	Pancreatic Aden... Recurrent Pancr... Stage III Pancr... Stage IV Pancre... Unresectable Pa...	Oxaliplatin Irinotecan Hydr... Leucovorin Calc... Fluorouracil Ascorbic Acid	18 Years - 75 Years	Thomas Jefferson University
Binimetinib and Encorafenib for the Treatment of Pancreatic Cancer in Patients With a Somatic BRAF V600E Mutation	NCT04390243	Locally Advance... Metastatic Panc... Recurrent Pancr... Stage III Pancr... Stage IV Pancre...	Binimetinib Encorafenib	18 Years -	Academic and Community Cancer Research United
Vismodegib and Gemcitabine Hydrochloride in Treating Patients With Advanced Pancreatic Cancer	NCT01195415	Recurrent Pancr... Stage IV Pancre...	Gemcitabine Hyd... Laboratory Biom... Vismodegib	18 Years -	National Cancer Institute (NCI)
Afatinib Dimaleate and Capecitabine in Treating Patients With Advanced Refractory Solid Tumors, Pancreatic Cancer or Biliary Cancer	NCT02451553	Advanced Malign... Bile Duct Carci... Recurrent Malig... Recurrent Pancr... Stage III Pancr... Stage IVA Pancr... Stage IVB Pancr...	Afatinib Dimale... Capecitabine Laboratory Biom...	19 Years -	University of Washington
Guadecitabine and Durvalumab in Treating Patients With Advanced Liver, Pancreatic, Bile Duct, or Gallbladder Cancer	NCT03257761	Extrahepatic Bi... Gallbladder Ade... Metastatic Panc... Recurrent Chola... Recurrent Gallb... Recurrent Hepat... Recurrent Intra... Recurrent Pancr... Stage III Gallb... Stage III Hepat... Stage III Intra... Stage III Pancr... Stage IIIA Gall... Stage IIIA Hepa... Stage IIIB Gall... Stage IIIB Hepa... Stage IIIC Hepa... Stage IV Gallbl... Stage IV Hepato... Stage IV Pancre... Stage IVA Gallb... Stage IVA Hepat... Stage IVA Intra... Stage IVB Gallb... Stage IVB Hepat... Stage IVB Intra... Unresectable Ga... Unresectable Pa...	Durvalumab Guadecitabine	18 Years -	University of Southern California
TLR8 Agonist VTX-2337 and Cyclophosphamide in Treating Patients With Metastatic, Persistent, Recurrent, or Progressive Solid Tumors	NCT02650635	Colorectal Aden... Metastatic Panc... Recurrent Breas... Recurrent Color... Recurrent Melan... Recurrent Non-S... Recurrent Pancr... Recurrent Renal... Solid Neoplasm Stage IV Breast... Stage IV Non-Sm... Stage IV Renal ... Stage IV Skin M... Stage IVA Color... Stage IVA Pancr... Stage IVB Color... Stage IVB Pancr...	Cyclophosphamid... Laboratory Biom... Pegfilgrastim Pharmacological... TLR8 Agonist VT...	18 Years -	Mayo Clinic
APN401 in Treating Patients With Recurrent or Metastatic Pancreatic Cancer, Colorectal Cancer, or Other Solid Tumors That Cannot Be Removed by Surgery	NCT03087591	Metastatic Mali... Metastatic Soli... Recurrent Color... Recurrent Pancr... Recurrent Solid... Stage IV Colore... Stage IV Pancre... Stage IVA Color... Stage IVA Pancr... Stage IVB Color... Stage IVB Pancr... Unresectable So...	Laboratory Biom... siRNA-transfect...	18 Years -	Wake Forest University Health Sciences
Pembrolizumab and XL888 in Patients With Advanced Gastrointestinal Cancer	NCT03095781	Colorectal Aden... Metastatic Panc... Recurrent Color... Recurrent Pancr... Stage III Color... Stage III Pancr... Stage IIIA Colo... Stage IIIB Colo... Stage IV Colore... Stage IV Pancre... Stage IVA Color... Stage IVA Pancr... Stage IVB Color... Stage IVB Pancr... Unresectable Pa...	XL888 Pembrolizumab	18 Years -	Emory University
Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors	NCT01131234	Adult Anaplasti... Adult Anaplasti... Adult Anaplasti... Adult Brain Ste... Adult Giant Cel... Adult Glioblast... Adult Gliosarco... Adult Mixed Gli... Adult Solid Neo... Male Breast Car... Recurrent Adult... Recurrent Breas... Recurrent Colon... Recurrent Melan... Recurrent Non-S... Recurrent Ovari... Recurrent Ovari... Recurrent Pancr... Recurrent Recta... Recurrent Renal... Stage III Pancr... Stage III Renal... Stage IIIA Colo... Stage IIIA Non-... Stage IIIA Ovar... Stage IIIA Ovar... Stage IIIA Rect... Stage IIIA Skin... Stage IIIB Brea... Stage IIIB Colo... Stage IIIB Non-... Stage IIIB Ovar... Stage IIIB Ovar... Stage IIIB Rect... Stage IIIB Skin... Stage IIIC Brea... Stage IIIC Colo... Stage IIIC Ovar... Stage IIIC Ovar... Stage IIIC Rect... Stage IIIC Skin... Stage IV Breast... Stage IV Non-Sm... Stage IV Ovaria... Stage IV Ovaria... Stage IV Pancre... Stage IV Renal ... Stage IV Skin M... Stage IVA Colon... Stage IVA Recta... Stage IVB Colon... Stage IVB Recta...	Gamma-Secretase... Cediranib Malea... Pharmacological... Laboratory Biom...	18 Years -	National Cancer Institute (NCI)
Dinaciclib and Akt Inhibitor MK2206 in Treating Patients With Pancreatic Cancer That Cannot Be Removed by Surgery	NCT01783171	Pancreatic Aden... Recurrent Pancr... Stage III Pancr... Stage IV Pancre... Unresectable Pa...	Akt Inhibitor M... Dinaciclib Laboratory Biom... Pharmacological...	18 Years -	National Cancer Institute (NCI)
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)	NCT02465060	Advanced Lympho... Advanced Malign... Bladder Carcino... Breast Carcinom... Cervical Carcin... Colon Carcinoma Colorectal Carc... Endometrial Car... Esophageal Carc... Gastric Carcino... Glioma Head and Neck C... Hematopoietic a... Kidney Carcinom... Liver Carcinoma Lung Carcinoma Lymphoma Malignant Uteri... Melanoma Multiple Myelom... Ovarian Carcino... Pancreatic Carc... Prostate Carcin... Rectal Carcinom... Recurrent Bladd... Recurrent Breas... Recurrent Cervi... Recurrent Colon... Recurrent Color... Recurrent Esoph... Recurrent Gastr... Recurrent Gliom... Recurrent Head ... Recurrent Liver... Recurrent Lung ... Recurrent Lymph... Recurrent Malig... Recurrent Melan... Recurrent Multi... Recurrent Ovari... Recurrent Pancr... Recurrent Prost... Recurrent Recta... Recurrent Skin ... Recurrent Thyro... Recurrent Uteri... Refractory Lymp... Refractory Mali... Refractory Mult... Skin Carcinoma Thyroid Gland C... Uterine Corpus ...	Adavosertib Afatinib Afatinib Dimale... Binimetinib Biopsy Biospecimen Col... Capivasertib Computed Tomogr... Copanlisib Copanlisib Hydr... Crizotinib Cytology Specim... Dabrafenib Dabrafenib Mesy... Dasatinib Defactinib Defactinib Hydr... Echocardiograph... Erdafitinib Fexagratinib Ipatasertib Laboratory Biom... Larotrectinib Larotrectinib S... Magnetic Resona... Multigated Acqu... Nivolumab Osimertinib Palbociclib Pertuzumab PI3K-beta Inhib... Radiologic Exam... Radionuclide Im... Relatlimab Sapanisertib Sunitinib Malat... Taselisib Trametinib Trastuzumab Trastuzumab Emt... Ulixertinib Vismodegib	18 Years -	National Cancer Institute (NCI)
Carboplatin and Paclitaxel With or Without Viral Therapy in Treating Patients With Recurrent or Metastatic Pancreatic Cancer	NCT01280058	Pancreatic Acin... Pancreatic Duct... Recurrent Pancr... Stage IV Pancre...	Carboplatin Laboratory Biom... Paclitaxel Wild-type Reovi...	18 Years -	National Cancer Institute (NCI)
Gemcitabine Hydrochloride, Dasatinib, and Erlotinib Hydrochloride in Treating Patients With Pancreatic Cancer That Is Metastatic or Cannot Be Removed by Surgery	NCT01660971	Metastatic Panc... Recurrent Pancr... Stage III Pancr... Stage IV Pancre...	Dasatinib Erlotinib Hydro... Gemcitabine Hyd...	18 Years -	National Cancer Institute (NCI)
Hypofractionated Stereotactic Body Radiation & Fluorouracil or Capecitabine for Locally Advanced Pancreatic Cancer	NCT03073785	Pancreatic Aden... Recurrent Pancr... Stage I Pancrea... Stage IA Pancre... Stage IB Pancre... Stage II Pancre... Stage IIA Pancr... Stage IIB Pancr... Stage III Pancr... Stage IV Pancre...	Capecitabine Fluorouracil Laboratory Biom... Pharmacological... Stereotactic Bo... Zoledronic Acid	19 Years -	University of Nebraska
Selumetinib and Akt Inhibitor MK2206 or mFOLFOX Therapy Comprising Oxaliplatin and Fluorouracil in Treating Patients With Metastatic Pancreatic Cancer Previously Treated With Chemotherapy	NCT01658943	Pancreatic Acin... Pancreatic Duct... Recurrent Pancr... Stage IV Pancre...	Akt Inhibitor M... Fluorouracil Oxaliplatin Selumetinib	18 Years -	National Cancer Institute (NCI)
Neoadjuvant Chemotherapy Followed by Radiation Therapy and Gemcitabine/Sorafenib/Vorinostat in Pancreatic Cancer	NCT02349867	Pancreatic Aden... Stage IA Pancre... Stage IB Pancre... Stage IIA Pancr... Stage IIB Pancr... Stage III Pancr... Recurrent Pancr...	Gemcitabine Sorafenib Vorinostat 3-Dimensional C... Intensity-Modul... RosetteSep DEPfff	18 Years -	Virginia Commonwealth University
Pembrolizumab and XL888 in Patients With Advanced Gastrointestinal Cancer	NCT03095781	Colorectal Aden... Metastatic Panc... Recurrent Color... Recurrent Pancr... Stage III Color... Stage III Pancr... Stage IIIA Colo... Stage IIIB Colo... Stage IV Colore... Stage IV Pancre... Stage IVA Color... Stage IVA Pancr... Stage IVB Color... Stage IVB Pancr... Unresectable Pa...	XL888 Pembrolizumab	18 Years -	Emory University

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: